Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Current Hematologic Malignancy Reports

Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)

Published in:
Authors
Katherine B. Case
Pamela B. Allen
Published in
Current Hematologic Malignancy Reports | Issue 1/2025

Abstract

Purpose of Review

Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common subtypes, accounting for the majority of CTCLs. There is no standard of care, and no treatments are curative. In this review, we summarize the promising, recently reported data describing novel systemic agents for the management of MF/SS.

Recent Findings

Clinical trials are currently exploring a number of agents, including novel chemotherapies, antibodies and antibody drug conjugates (ADCs), immunotherapy, and cellular therapies.

Summary

These promising novel agents may expand the treatment landscape for MF/SS.
Title
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)
Authors
Katherine B. Case
Pamela B. Allen
Publication date
01-12-2025
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 1/2025
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-024-00746-7
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 1/2025

Monoclonal Gammopathy-Associated Neuropathy

Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms

Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review

Contemporary CMML Risk Stratification and Management

  • Review

Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance

The Role of Inflammation in CMML Pathobiology and Progression

Keynote webinar | Spotlight on progress in colorectal cancer

On-demand video coming soon

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Prof. Antoni Castells
Prof. Harpreet Wasan
Prof. Edward Giovannucci
Notify me

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video
Image Credits
Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images, Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images